WebDoctor Encyclopedia

Breast Invasive carcinoma Special types

Metaplastic breast carcinoma

Metaplastic breast carcinoma is a rare, aggressive breast cancer in which some cancer cells change into squamous, spindle or bone- and cartilage-like cells. It is usually triple-negative, often large at diagnosis and responds less well to chemotherapy.

Medically reviewed Last reviewed October 27, 2026

What is metaplastic breast carcinoma?

Metaplastic breast carcinoma (MBC) is a rare and usually aggressive type of breast cancer. It accounts for under 1% of all breast cancers.

The word “metaplastic” means that some of the cancer cells have changed into a different type of cell. Part of the tumour still looks like breast gland tissue, but other parts look like skin-type (squamous) cells, spindle-shaped cells, or even cartilage or bone. Doctors call this mix of appearances “divergent differentiation”.

Most metaplastic breast cancers are triple-negative. This means the cancer cells do not have receptors for oestrogen, progesterone or HER2, so hormone therapy and HER2-targeted drugs do not work. Metaplastic tumours also tend to respond less well to chemotherapy than other triple-negative breast cancers (Aydiner et al., 2015).

MBC often presents as a large, fast-growing lump. Compared with common breast cancers, it spreads to lymph nodes less often but more often travels through the bloodstream to the lungs and brain. Reviews describe it as an aggressive cancer with a less favourable outlook than most breast cancers (Thomas et al., 2023). Treatment combines surgery, chemotherapy and radiotherapy, and newer drugs such as immunotherapy are increasingly used.

1. Key facts at a glance

Feature Details
Type of cancer Special type of invasive breast carcinoma
How common Rare; about 0.2-1% of breast cancers
Typical age Usually 50-65; median late 50s
Sex Almost always women; very rare in men
Receptor status Triple-negative in about 9 in 10
Typical size at diagnosis Often larger than 3-4 cm
Usual spread Lungs, bone, brain and liver more than lymph nodes
Main treatment Surgery, chemotherapy, radiotherapy; immunotherapy in selected cases
Outlook Worse than most breast cancers; depends strongly on stage and subtype

2. Types of metaplastic breast carcinoma

The World Health Organization recognises several subtypes, which behave quite differently.

Subtype Description Behaviour
Low-grade adenosquamous carcinoma Small glands and squamous nests in a scar-like background Low grade; mostly local recurrence
Fibromatosis-like metaplastic carcinoma Bland spindle cells resembling scar tissue Low grade; can recur locally
Squamous cell carcinoma Skin-type cells, often around a cyst Aggressive
Spindle cell carcinoma Long, spindle-shaped tumour cells Aggressive
With heterologous mesenchymal differentiation Areas of cartilage (chondroid), bone (osseous) or other tissue Aggressive; matrix-producing type may have a somewhat better outlook
Mixed metaplastic carcinoma Combination of the above Aggressive

Knowing the subtype matters, because the low-grade forms have a much better outlook than high-grade forms (Khoury, 2023).

3. Causes and risk factors

As with other breast cancers, the exact cause is not known.

Risk factor Notes
Increasing age Most patients are past the menopause
Female sex Almost all cases occur in women
Inherited BRCA1 variants Linked with triple-negative breast cancers, including some metaplastic cancers
Previous radiation to the chest A general risk factor for breast cancer
Family history Raises breast cancer risk in general

Gene changes in the tumour

Gene change Approximate frequency Notes
TP53 mutation Common Linked with high-grade behaviour
PIK3CA and PI3K pathway changes More common than in other triple-negative cancers A possible drug target
Epithelial-mesenchymal transition (EMT) features Typical Helps explain the mixed cell types and chemotherapy resistance
PD-L1 expression Present in a proportion Relevant to immunotherapy

Why MBC behaves differently

Metaplastic cancer cells have undergone a process called epithelial-mesenchymal transition, in which lining-type cells take on features of connective tissue cells. Cells that have made this change tend to move and invade more easily, resist chemotherapy and spread through the bloodstream rather than the lymph channels. This helps explain the larger tumours, the lower rate of armpit node spread and the higher rate of lung and brain metastases seen in this cancer (Yan, Deng and Zhang, 2024).

4. How does it look

In the breast

Feature Description
Lump A firm, well-defined or lobulated mass
Size Often larger than other breast cancers at diagnosis
Growth Can enlarge noticeably over weeks
Skin May become stretched, red or ulcerated over large tumours
Cystic areas Common, especially in squamous types

On scans

Scan Typical findings
Mammogram A round or oval, fairly well-defined mass; calcifications less common
Ultrasound A solid mass, often with cystic or necrotic areas, which can look deceptively benign
MRI A mass with strong rim enhancement and central necrosis
CT or PET-CT Used to check for spread to the lungs, bone and liver

Because MBC can look round and fairly smooth on scans, it may at first be mistaken for a benign fibroadenoma or a cyst. Any new solid lump in an adult woman should be biopsied.

Under the microscope

Feature Description
Components Areas of ordinary breast carcinoma mixed with squamous, spindle, cartilage-like or bone-like tissue
Grade Usually high grade, with many dividing cells and necrosis
Receptors Usually negative for oestrogen, progesterone and HER2
Stains Keratins (sometimes only patchy) and p63 help confirm that spindle cells are carcinoma, not sarcoma

5. Symptoms

Common symptoms

  • A lump in the breast, often firm and growing quickly
  • Change in the size or shape of the breast
  • Skin changes, such as redness, dimpling or a sore that does not heal
  • Breast pain in some people
  • A lump in the armpit, less often than in other breast cancers

Symptoms of spread

Site Possible symptoms
Lungs Cough, breathlessness, chest pain
Bone Bone pain, fracture
Brain Headache, sickness, weakness, seizures, confusion
Liver Tummy discomfort, jaundice, weight loss

When to seek medical advice

See a doctor about any new breast lump, a change in the breast or nipple, or skin changes that do not settle. Breast clinics can usually examine, scan and biopsy a lump on the same day. Do not wait for a routine screening appointment if you notice a change.

6. Diagnosis

Test Purpose
Clinical examination Checks the breast and lymph nodes
Mammogram and ultrasound Shows the lump and guides biopsy
Core needle biopsy Confirms cancer and shows the subtype
Receptor testing Oestrogen, progesterone and HER2 status
Breast MRI Measures tumour size and checks the rest of the breast
CT chest, abdomen and pelvis, bone scan or PET-CT Looks for distant spread, often recommended because MBC spreads through the blood
Genetic testing BRCA and other genes, especially for triple-negative cancers
PD-L1 and other biomarkers Guide immunotherapy and targeted treatment

Diagnostic challenges

Spindle cell types can look very similar to sarcomas or phyllodes tumours. Pathologists use several keratin stains and p63 to show that the cells came from breast lining tissue. A small biopsy may not show every component, so the final subtype is often confirmed after surgery.

Staging

Metaplastic breast cancer is staged in the same way as other breast cancers, using tumour size (T), lymph node involvement (N) and distant spread (M), together with grade and receptor status.

Stage Meaning in simple terms
Stage I Small tumour (up to 2 cm), no or minimal node spread
Stage II Tumour 2-5 cm, or a smaller tumour with a few involved nodes
Stage III Large tumour, skin or chest wall involvement, or extensive node spread
Stage IV Spread to distant organs such as lungs, bone, liver or brain

Because the tumours are often large, many people with MBC are diagnosed at stage II or III.

7. Treatment

Treatment is planned by a breast cancer multidisciplinary team.

Surgery

Option Notes
Breast-conserving surgery (lumpectomy) Possible for smaller tumours, followed by radiotherapy
Mastectomy Often needed because tumours are large
Sentinel lymph node biopsy Checks the first nodes draining the breast
Axillary clearance If several nodes contain cancer
Breast reconstruction Immediate or delayed

Chemotherapy

Chemotherapy is recommended for most high-grade metaplastic cancers. It may be given before surgery (neoadjuvant) to shrink the tumour, or after surgery (adjuvant). Typical regimens include anthracyclines, cyclophosphamide, taxanes and platinum drugs.

MBC is often resistant to standard chemotherapy. In an Istanbul study that matched 54 people with MBC to similar patients with triple-negative ductal cancer, those with metaplastic cancer had clearly worse results at 3 years: about 51% versus 82% were free of progression, and 68% versus 94% were alive (Aydiner et al., 2015). Taxane-containing regimens and radiotherapy were linked with better outcomes in that study. Because responses can be disappointing, teams monitor the tumour closely when chemotherapy is given before surgery, and some prefer surgery first for tumours that can be removed easily.

Radiotherapy

Radiotherapy is given after breast-conserving surgery and after mastectomy for large tumours or node-positive disease. It lowers the risk of the cancer returning in the breast area.

Immunotherapy and targeted treatment

Treatment Notes
Pembrolizumab with chemotherapy Standard for high-risk early triple-negative breast cancer; also used for advanced PD-L1-positive disease
Sacituzumab govitecan An antibody-drug conjugate used for advanced triple-negative breast cancer
PARP inhibitors (olaparib) For people with inherited BRCA variants
PI3K pathway drugs Being studied in trials for metaplastic cancers
Clinical trials Recommended where available

Side effects

Treatment Possible side effects
Surgery Pain, wound problems, arm swelling (lymphoedema), numbness
Chemotherapy Hair loss, tiredness, infections, sickness, nerve tingling
Radiotherapy Skin redness, tiredness, breast firmness
Immunotherapy Inflammation of the thyroid, bowel, lungs, liver or skin
Antibody-drug conjugates Low blood counts, diarrhoea, hair loss

What treatment involves day to day

Part of treatment What to expect
Surgery Lumpectomy is often a day case; mastectomy usually means 1-3 nights in hospital
Chemotherapy Treatment every 1-3 weeks for about 4-6 months, given in a day unit
Immunotherapy Infusions every 3-6 weeks, sometimes continued for up to a year
Radiotherapy Weekday sessions for 1-3 weeks with modern short schedules

8. Outlook (prognosis)

Situation General outlook
Low-grade subtypes Good; mainly a risk of local recurrence
High-grade, early-stage disease Many people are cured, but the risk of recurrence is higher than for most breast cancers
Large tumours or node-positive disease Higher risk of spread
Metastatic disease Serious; responses to treatment are often short

When compared with matched triple-negative breast cancers, MBC has shown shorter survival; in one study, 3-year overall survival was 68% for MBC and 94% for the comparison group (Aydiner et al., 2015). Recurrences usually happen within the first 2-3 years, so the first years of follow-up are the most important.

9. Follow-up

Follow-up Purpose
Clinic visits every 3-6 months for 2-3 years Examination and symptom review
Yearly mammogram Checks the treated and other breast
Scans if symptoms appear Look for spread to lungs, bone, liver or brain
Management of long-term effects Heart, bone and nerve health, menopause symptoms

10. Living with metaplastic breast carcinoma

  • Report new symptoms early, especially cough, bone pain or headaches
  • Ask about lymphoedema prevention after lymph node surgery
  • Keep active, which helps with tiredness and wellbeing
  • Ask about genetic testing if not already done
  • Consider clinical trials, as research in this rare cancer is active
  • Seek support from breast cancer charities, specialist nurses and support groups

11. Frequently asked questions

Question Answer
Is metaplastic breast cancer the same as triple-negative? Most are triple-negative, but MBC is a distinct special type
Why is it treated differently? It responds less well to chemotherapy and spreads more often through the blood
Will I need hormone therapy? Usually not, because the cancer lacks hormone receptors
Is it inherited? Usually not, but some patients carry BRCA1 or other variants
Can men get it? Extremely rarely
Are low-grade types dangerous? They rarely spread but can come back in the breast

12. Questions to ask your care team

  • Which subtype of metaplastic carcinoma do I have?
  • Is it triple-negative, and what is the PD-L1 result?
  • Should I have chemotherapy before or after surgery?
  • Would immunotherapy be suitable?
  • Should I have genetic testing?
  • Are there clinical trials I could join?

Resources

  1. Aydiner, A. et al. (2015) ‘Metaplastic breast carcinoma versus triple-negative breast cancer: survival and response to treatment’, Medicine, 94(52), e2341.
  2. Khoury, T. (2023) ‘Metaplastic breast carcinoma revisited; subtypes determine outcomes: comprehensive pathologic, clinical, and molecular review’, Clinics in Laboratory Medicine, 43(2), pp. 221-243.
  3. Thomas, H.R. et al. (2023) ‘Metaplastic breast cancer: a review’, Critical Reviews in Oncology/Hematology, 182, 103924.
  4. Yan, Q., Deng, Y. and Zhang, Q. (2024) ‘A comprehensive overview of metaplastic breast cancer: features and treatments’, Cancer Science, 115(8), pp. 2506-2514.
  5. National Cancer Institute (2026) Breast Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/breast/hp/breast-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.